WHAT: U.S. Genomics will give a product demonstration of the Trilogy™ Single Molecule Analyzer and assays on the exhibit floor of the Drug Discovery Technology Conference in Boston on August 10, 9:40 AM. The Trilogy™ platform, the Company’s first commercially available product, permits direct comparison among different molecules without amplification, eliminating the inequalities that may arise through conventional measurements.

WHO: Dr. Jeff Randall from U.S. Genomics will present the Trilogy™ platform at Drug Discovery Technology in Boston on August 10, 9:40 AM, Stage #1, Exhibit Hall D, Hynes Convention Center. David Hoey, VP of Business Development, will also be available for comment.

BACKGROUND: Single molecule biology is critical to breakthrough therapies and more accurate diagnostics for the healthcare industry because such advances depend on understanding how cellular material functions and interacts at the molecular level. Understanding how biological pathways manifest themselves differently in normal and diseased states hinges on a researcher’s ability to detect these small variances.

By offering direct analysis of molecules, the Trilogy™ platform will enable important biological research that is beyond the reach of currently available research tools.

The Trilogy™ technology combines advances in nanofluidics, optical engineering, and novel labeling strategies with life science applications in research, drug discovery and development, and diagnostics. The first applications of U.S. Genomics’ platform include direct detection and analysis of RNA, small RNAs (siRNA, miRNA, etc), and protein molecules as well as analyses of the molecules’ interactions.



ABOUT US GENOMICS U.S. Genomics, Woburn, Mass., intends to become the world’s leading provider of technologies that allow genetics, functional genomics, and diagnostics to be performed at the single molecule level, by offering instruments and reagents that enable researchers to understand biology directly. The technology has life sciences applications in the areas of research, drug discovery and development, and diagnostics, and longer term it will provide a platform to advance our understanding of diseases in order to tailor drug development. Please visit www.usgenomics.com.